Ramucirumab – A New Treatment Option

The FDA approved the use of the drug ramucirumab (brand name Cyramza®) on April 24, 2015 for patients with metastatic colorectal cancer in combination with FOLFIRI. Ramucirumab with FOLFIRI is now approved for patients whose cancer has progressed during or…  Read More

Erbitux Approved as First-Line Treatment

The FDA has approved Erbitux™ (cetuximab) in combination with FOLFIRI for first-line treatment of patients with metastatic colorectal cancer whose tumors have a wild-type (WT) KRAS gene.  Erbitux was first approved in 2004 for patients whose cancer was not responding to…  Read More

Avastin with XELIRI or FOLFIRI: Is There Any Difference?

When Avastin is added to the combination of Xeloda and irinotecan as an initial treatment for advanced colorectal cancer, the treatment is equally effective as Avastin with FOLFIRI. But side effects are more difficult. After a randomized clinical trial comparing…  Read More